(19)
(11) EP 4 436 590 A1

(12)

(43) Date of publication:
02.10.2024 Bulletin 2024/40

(21) Application number: 22826205.1

(22) Date of filing: 23.11.2022
(51) International Patent Classification (IPC): 
A61K 36/756(2006.01)
A61K 31/4375(2006.01)
A61P 13/08(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 36/756; A61P 13/08; A61P 35/00
 
C-Sets:
A61K 36/756, A61K 2300/00;
(86) International application number:
PCT/IB2022/061340
(87) International publication number:
WO 2023/095024 (01.06.2023 Gazette 2023/22)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 24.11.2021 IT 202100029771

(71) Applicant: Hauora Med S.r.l. in Breve Hauora S.r.l.
20123 Milan (IT)

(72) Inventor:
  • BURATTI, Ermanno
    20123 Milan (IT)

(74) Representative: Hoffmann Eitle 
Hoffmann Eitle S.R.L. Piazza Sigmund Freud 1
20154 Milano
20154 Milano (IT)

   


(54) COMPOSITION COMPRISING NEXRUTINE FOR USE IN PATIENTS WITH EARLY PROSTATE CANCER